Viewing Study NCT06305767


Ignite Creation Date: 2025-12-25 @ 12:36 AM
Ignite Modification Date: 2026-01-20 @ 10:11 PM
Study NCT ID: NCT06305767
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2024-03-05
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module